{"downloaded": true, "htmlmade": false, "full": {"id": "29515114", "source": "MED", "pmid": "29515114", "pmcid": "PMC5841331", "fullTextIdList": {"fullTextId": "PMC5841331"}, "doi": "10.1038/s41408-018-0067-6", "title": "Momelotinib therapy for myelofibrosis: a 7-year follow-up.", "authorString": "Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A.", "authorList": {"author": [{"fullName": "Tefferi A", "firstName": "Ayalew", "lastName": "Tefferi", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu."}}}, {"fullName": "Barraco D", "firstName": "Daniela", "lastName": "Barraco", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Lasho TL", "firstName": "Terra L", "lastName": "Lasho", "initials": "TL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Shah S", "firstName": "Sahrish", "lastName": "Shah", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Begna KH", "firstName": "Kebede H", "lastName": "Begna", "initials": "KH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Al-Kali A", "firstName": "Aref", "lastName": "Al-Kali", "initials": "A", "authorId": {"@type": "ORCID", "#text": "0000-0002-0824-3715"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Hogan WJ", "firstName": "William J", "lastName": "Hogan", "initials": "WJ", "authorId": {"@type": "ORCID", "#text": "0000-0002-5841-4105"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Litzow MR", "firstName": "Mark R", "lastName": "Litzow", "initials": "MR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Hanson CA", "firstName": "Curtis A", "lastName": "Hanson", "initials": "CA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Ketterling RP", "firstName": "Rhett P", "lastName": "Ketterling", "initials": "RP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Gangat N", "firstName": "Naseema", "lastName": "Gangat", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Pardanani A", "firstName": "Animesh", "lastName": "Pardanani", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-0824-3715"}, {"@type": "ORCID", "#text": "0000-0002-5841-4105"}]}, "dataLinksTagsList": {"dataLinkstag": ["related_data", "supporting_data"]}, "journalInfo": {"issue": "3", "volume": "8", "journalIssueId": "2659464", "dateOfPublication": "2018 Mar", "monthOfPublication": "3", "yearOfPublication": "2018", "printPublicationDate": "2018-03-01", "journal": {"title": "Blood cancer journal", "ISOAbbreviation": "Blood Cancer J", "medlineAbbreviation": "Blood Cancer J", "NLMid": "101568469", "ISSN": "2044-5385", "ESSN": "2044-5385"}}, "pubYear": "2018", "pageInfo": "29", "abstractText": "One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinued in 91% of the patients, after a median treatment duration of 1.4 years. Grade 3/4 toxicity included thrombocytopenia (34%) and liver/pancreatic test abnormalities (<10%); grade 1/2 peripheral neuropathy occurred in 47%. Clinical improvement (CI) occurred in 57% of patients, including 44% anemia and 43% spleen response. CI was more likely to occur in ASXL1-unmutated patients (66% vs 44%) and in those with <2% circulating blasts (66% vs 42%). Response was more durable in the presence of CALR type 1/like and absence of very high-risk karyotype. In multivariable analysis, absence of CALR type 1/like (HR 3.0; 95% CI 1.2-7.6) and presence of ASXL1 (HR 1.9; 95% CI 1.1-3.2) or SRSF2 (HR 2.4, 95% CI 1.3-4.5) mutations adversely affected survival. SRSF2 mutations (HR 4.7, 95% CI 1.3-16.9), very high-risk karyotype (HR 7.9, 95% CI 1.9-32.1), and circulating blasts \u22652% (HR 3.9, 95% CI 1.4-11.0) predicted leukemic transformation. Post-MMB survival (median 3.2 years) was not significantly different than that of a risk-matched MF cohort not receiving MMB.", "affiliation": "Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Benzamides", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Pyrimidines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Follow-Up Studies"}, {"majorTopic_YN": "N", "descriptorName": "Mutation"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Janus Kinase 2", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Primary Myelofibrosis", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "Y"}]}}]}, "chemicalList": {"chemical": [{"name": "Pyrimidines", "registryNumber": "0"}, {"name": "Benzamides", "registryNumber": "0"}, {"name": "JAK2 protein, human", "registryNumber": "EC 2.7.10.2"}, {"name": "Janus Kinase 2", "registryNumber": "EC 2.7.10.2"}, {"name": "N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide", "registryNumber": "6O01GMS00P"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41408-018-0067-6"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5841331"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5841331?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "11", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "Y", "dbCrossReferenceList": {"dbName": "CHEBI"}, "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2018-08-30", "dateOfCreation": "2018-03-09", "firstIndexDate": "2018-03-09", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2020-03-06", "electronicPublicationDate": "2018-03-07", "firstPublicationDate": "2018-03-07"}, "htmllinks": "https://europepmc.org/articles/PMC5841331", "abstract": "One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinued in 91% of the patients, after a median treatment duration of 1.4 years. Grade 3/4 toxicity included thrombocytopenia (34%) and liver/pancreatic test abnormalities (<10%); grade 1/2 peripheral neuropathy occurred in 47%. Clinical improvement (CI) occurred in 57% of patients, including 44% anemia and 43% spleen response. CI was more likely to occur in ASXL1-unmutated patients (66% vs 44%) and in those with <2% circulating blasts (66% vs 42%). Response was more durable in the presence of CALR type 1/like and absence of very high-risk karyotype. In multivariable analysis, absence of CALR type 1/like (HR 3.0; 95% CI 1.2-7.6) and presence of ASXL1 (HR 1.9; 95% CI 1.1-3.2) or SRSF2 (HR 2.4, 95% CI 1.3-4.5) mutations adversely affected survival. SRSF2 mutations (HR 4.7, 95% CI 1.3-16.9), very high-risk karyotype (HR 7.9, 95% CI 1.9-32.1), and circulating blasts \u22652% (HR 3.9, 95% CI 1.4-11.0) predicted leukemic transformation. Post-MMB survival (median 3.2 years) was not significantly different than that of a risk-matched MF cohort not receiving MMB.", "pdflinks": "https://europepmc.org/articles/PMC5841331?pdf=render", "journaltitle": "Blood cancer journal", "authorinfo": ["Tefferi A", "Barraco D", "Lasho TL", "Shah S", "Begna KH", "Al-Kali A", "Hogan WJ", "Litzow MR", "Hanson CA", "Ketterling RP", "Gangat N", "Pardanani A"], "title": "Momelotinib therapy for myelofibrosis: a 7-year follow-up."}